Can gene therapy slow a rare, fatal childhood brain disease? Early trial shows some signs it might.

Imagine watching your child lose the ability to move and communicate because of a rare, fatal brain disease with no treatment. That's the reality of GM1 gangliosidosis. In a first-of-its-kind trial with nine children, doctors tested a single dose of gene therapy delivered into the bloodstream. The goal was to replace the missing enzyme that causes toxic buildup in the brain. The treatment wasn't easy. All children had elevated liver enzymes that took up to 18 months to return to normal, and one child was hospitalized for severe vomiting linked to the therapy. But there were hopeful signs. The toxic substance in the spinal fluid went down, and the needed enzyme went up. Brain scans suggested the rate of brain shrinkage slowed and there were positive changes in the brain's wiring. While skills like expressive communication and large movements appeared stable, fine motor skills and understanding language still declined. Overall, doctors rated the children as having minimal improvement or no change over 2-3 years, which is notable because without treatment, children with this disease typically get much worse. This early trial shows the therapy engages with the disease and may alter its course, offering a crucial first step for families desperate for options.